Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, Hepatol, vol.64, pp.73-84, 2016.

P. Angulo, D. E. Kleiner, S. Dam-larsen, L. A. Adams, E. S. Bjornsson et al., Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease, Gastroenterology, vol.149, issue.2, pp.389-397, 2015.

E. Vilar-gomez, Y. Martinez-perez, L. Calzadilla-bertot, A. Torres-gonzalez, B. Gra-oramas et al., Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis, Gastroenterology, vol.149, pp.367-78, 2015.

M. Seghieri, A. S. Christensen, A. Andersen, A. Solini, F. K. Knop et al., Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD, Front. Endocrinol, vol.9, p.649, 2018.

, 9 Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis

M. J. Armstrong, P. Gaunt, G. P. Aithal, D. Barton, D. Hull et al., Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study, Lancet, vol.387, pp.679-90, 2016.

M. H. Tschöp, B. Finan, C. Clemmensen, V. Gelfanov, D. Perez-tilve et al., Unimolecular Polypharmacy for Treatment of Diabetes and Obesity, Cell Metab, vol.24, issue.1, pp.51-62, 2016.

J. W. Day, N. Ottaway, J. T. Patterson, V. Gelfanov, D. Smiley et al., A new glucagon and GLP-1 co-agonist eliminates obesity in rodents, Nat Chem Biol, vol.5, pp.749-57, 2009.

S. J. Henderson, A. Konkar, D. C. Hornigold, J. L. Trevaskis, R. Jackson et al., Robust antiobesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and nonhuman primates, Diab Obes Metab, vol.18, pp.1176-90, 2016.

P. Ambery, V. E. Parker, M. Stumvoll, M. G. Posch, T. Heise et al., MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, doubleblind, ascending dose and phase 2a study, Lancet, vol.391, pp.2607-2618, 2018.

B. Finan, T. Ma, N. Ottaway, T. D. Muller, K. M. Habegger et al., Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans, Sci Transl Med, vol.5, pp.209-151, 2013.

S. Jall, S. Sachs, C. Clemmensen, B. Finan, F. Neff et al.,

, Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice, Mol Metab, vol.6, pp.440-446, 2017.

M. N. Kristiansen, S. S. Veidal, K. T. Rigbolt, K. S. Tølbøl, J. D. Roth et al., Obese dietinduced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy, World J Hepatol, vol.8, pp.673-84, 2016.

J. R. Clapper, M. D. Hendricks, G. Gu, C. Wittmer, C. S. Dolman et al., Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment, Am J Physiol Gastrointest Liver Physiol, vol.305, pp.483-95, 2013.

D. E. Kleiner, E. M. Brunt, M. Van-natta, C. Behling, M. J. Contos et al.,

, Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, vol.41, pp.1313-1334, 2005.

A. Evers, T. Haack, M. Lorenz, M. Bossart, R. Elvert et al., Design of Novel Exendin-Based Dual Glucagon-like Peptide, vol.1

. /glucagon-receptor and . Agonists, J Med Chem, vol.60, p.5941, 2017.

R. Elvert, A. W. Herling, M. Bossart, T. Weiss, B. Zhang et al., Running on mixed fueldual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates, Diabetes Obes Metab, vol.20, pp.1836-1851, 2018.

R. Elvert, M. Bossart, A. W. Herling, T. Weiss, B. Zhang et al., Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys, Endocrinology, vol.159, pp.3105-3119, 2018.

P. Lefebvre, F. Lalloyer, E. Baugé, M. Pawlak, C. Gheeraert et al., Interspecies NASH disease activity whole-genome profiling identifies a fibrogenic role of PPAR?regulated dermatopontin, JCI Insight, vol.2, p.92264, 2017.

X. Pi-sunyer, A. Astrup, K. Fujioka, F. Greenway, A. Halpern et al., Wilding JP; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management, N Engl J Med, vol.373, pp.11-22, 2015.

L. Blonde, R. , and D. , The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies, Diabetes Obes Metab, vol.11, issue.3, pp.26-34, 2009.

F. K. Knop, A. Brønden, and T. Vilsbøll, Exenatide: pharmacokinetics, clinical use, and future directions, Expert Opin Pharmacother, vol.18, pp.555-571, 2017.

V. A. Fonseca, R. Alvarado-ruiz, D. Raccah, G. Boka, P. Miossec et al., EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono), Diabetes Care, vol.35, pp.1225-1256, 2012.

G. Umpierrez, T. Povedano, S. , P. Manghi, F. Shurzinske et al., Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3), Diabetes Care, vol.37, pp.2168-76, 2014.

M. A. Nauck, M. W. Stewart, C. Perkins, A. Jones-leone, Y. F. Perry et al., Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise, Diabetologia, vol.59, pp.266-74, 2016.

A. J. Ahmann, M. Capehorn, G. Charpentier, F. Dotta, E. Henkel et al., Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2

, A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, vol.41, issue.3, pp.258-266, 2018.

S. P. Marso, G. H. Daniels, K. Brown-frandsen, P. Kristensen, J. F. Mann et al., Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med, vol.375, pp.311-333, 2016.

S. P. Marso, S. C. Bain, A. Consoli, F. G. Eliaschewitz, E. Jódar et al., Vilsbøll T; SUSTAIN-6 Investigators. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.375, pp.1834-1844, 2016.

A. F. Hernandez, J. B. Green, S. Janmohamed, D. Sr, C. B. Granger et al., Del Prato S; Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet, vol.392, pp.1519-1529, 2018.

M. Husain, A. L. Birkenfeld, M. Donsmark, K. Dungan, F. G. Eliaschewitz et al.,

. Investigators, Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, vol.381, pp.841-851, 2019.

H. C. Gerstein, H. M. Colhoun, G. R. Dagenais, R. Diaz, M. Lakshmanan et al., Temelkova-Kurktschiev T; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, vol.394, pp.121-130, 2019.

J. Tillner, M. G. Posch, F. Wagner, L. Teichert, Y. Hijazi et al., A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials, Diabetes Obes Metab, vol.21, pp.120-128, 2019.

J. P. Frias, M. A. Nauck, J. Van, M. E. Kutner, X. Cui et al., Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial, Lancet, vol.392, pp.2180-2193, 2018.

J. L. Trevaskis, P. S. Griffin, C. Wittmer, B. A. Neuschwander-tetri, E. M. Brunt et al., Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice, Am J Physiol Gastrointest Liver Physiol, vol.302, pp.762-72, 2012.

S. J. Daniels, D. J. Leeming, S. Detlefsen, M. F. Bruun, S. T. Hjuler et al., Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis -Effects of a peroxisome proliferator-activated receptor gamma (PPAR-?) agonist and a glucagon-like peptide-1 analogue, Biomed Pharmacother, vol.111, pp.926-933, 2019.

M. P. Valdecantos, L. Ruiz, V. Pardo, L. Castro-sanchez, C. García-monzón et al., Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to, Hepatectomy. Sci Rep, vol.8, p.16461, 2018.

D. H. Ipsen, B. Rolin, G. Rakipovski, G. F. Skovsted, A. Madsen et al., Liraglutide Decreases Hepatic Inflammation and Injury in Advanced Lean Non-Alcoholic Steatohepatitis, Basic Clin Pharmacol Toxicol, vol.123, pp.704-713, 2018.

K. S. Tølbøl, M. N. Kristiansen, H. H. Hansen, S. S. Veidal, K. T. Rigbolt et al., Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis, World J Gastroenterol, vol.24, pp.179-194, 2018.

T. Yamamoto, Y. Nakade, T. Yamauchi, Y. Kobayashi, N. Ishii et al., Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice, World J Gastroenterol, vol.22, pp.2512-2535, 2016.

M. P. Valdecantos, V. Pardo, L. Ruiz, L. Castro-sánchez, B. Lanzón et al., A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice, Hepatology, vol.65, pp.950-968, 2017.

G. Lassailly, R. Caiazzo, D. Buob, M. Pigeyre, H. Verkindt et al., Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients, Gastroenterology, vol.149, pp.379-88, 2015.

T. D. Müller, B. Finan, C. Clemmensen, R. D. Dimarchi, and M. H. Tschöp, The New Biology and Pharmacology of Glucagon, Physiol Rev, vol.97, pp.721-766, 2017.

, US Food and Drug Administration, Final Determination Regarding Partially Hydrogenated Oils (Removing Trans Fat), 2018.

M. L. Boland, D. Oró, K. S. Tølbøl, S. T. Thrane, J. C. Nielsen et al., Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source, World J Gastroenterol, vol.25, pp.4904-4920, 2019.